Teva Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?
TEVA has seven hundred and forty approved drugs.
There are one hundred and three US patents protecting TEVA drugs. There are fifty-three tentative approvals on TEVA drugs.
There are nine hundred and forty-four patent family members on TEVA drugs in forty-nine countries and one thousand and eighty-five supplementary protection certificates in eighteen countries.
Summary for Teva
| International Patents: | 944 |
| US Patents: | 103 |
| Tradenames: | 510 |
| Ingredients: | 445 |
| NDAs: | 740 |
| Patent Litigation for Teva: | See patent lawsuits for Teva |
| PTAB Cases with Teva as petitioner: | See PTAB cases with Teva as petitioner |
Drugs and US Patents for Teva
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | DISCN | Yes | No | 9,731,087*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-002 | Jan 27, 2017 | RX | Yes | No | 9,987,229*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva | DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 077488-003 | Apr 29, 2013 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-005 | Feb 20, 2020 | DISCN | Yes | No | 11,464,923*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva Parenteral | AZITHROMYCIN | azithromycin | INJECTABLE;INJECTION | 050809-002 | Dec 19, 2006 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-006 | Feb 20, 2020 | 6,701,917 | ⤷ Sign Up |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 6,939,539 | ⤷ Sign Up |
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-001 | Jan 27, 2017 | 6,701,917 | ⤷ Sign Up |
| Teva Branded Pharm | SEASONALE | ethinyl estradiol; levonorgestrel | TABLET;ORAL | 021544-001 | Sep 5, 2003 | RE39861 | ⤷ Sign Up |
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-005 | Jul 12, 2019 | 6,701,917 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 20 mg, 30 mg | ➤ Subscribe | 2009-11-18 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
| ➤ Subscribe | Tablets | 0.15 mg/0.03 mg/0.01 mg | ➤ Subscribe | 2008-01-22 |
| ➤ Subscribe | Tablets | 0.1 mg/0.02 mg and 0.01 mg | ➤ Subscribe | 2009-11-16 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-17 |
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
| ➤ Subscribe | Tablets | 0.15 mg/0.03 mg | ➤ Subscribe | 2004-03-29 |
| ➤ Subscribe | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | ➤ Subscribe | 2013-07-10 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Tablets | 1 mg/0.02 mg and 75 mg | ➤ Subscribe | 2006-04-17 |
Premature patent expirations for TEVA
International Patents for Teva Drugs
Supplementary Protection Certificates for Teva Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0136011 | 2000C/027 | Belgium | ⤷ Sign Up | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 |
| 2498758 | 2020C/509 | Belgium | ⤷ Sign Up | PRODUCT NAME: QTRILMET - METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113 |
| 1613288 | C20110013 00043 | Estonia | ⤷ Sign Up | PRODUCT NAME: GILENYA - FINGOLIMOD; REG NO/DATE: FINAL 17.03.2011 |
| 1304992 | C01304992/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014 |
| 1047694 | CA 2008 00040 | Denmark | ⤷ Sign Up | PRODUCT NAME: LAPATINIB ELLER ET SALT ELLER SOLVAT DERAF, HERUNDER LAPATINIBDITOSYLATMONOHYDRAT |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
